Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Cohort studyAmerican journal of ophthalmology· Aug 2026

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco, Fangming Jin, Ali G Hamedani, Brian L VanderBeek

Read paper

UveitisCohort studyTreatmentQ1IF 4.2

Nucleic acid synthesis inhibitors/S1P modulators linked to much lower uveitis risk in multiple sclerosis

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco … Brian L VanderBeek

American journal of ophthalmology · Aug 2026 · Q1 in Ophthalmology

Background

Whether disease-modifying therapies (disease-modifying therapies) for multiple sclerosis alter this risk is unknown.

Purpose

Multiple sclerosis (multiple sclerosis) is associated with an increased risk of noninfectious uveitis (noninfectious uveitis).

Methods

Adults with multiple sclerosis, defined by ≥3 diagnosis codes on separate dates, who received ≥1 disease-modifying therapies prescription and had ≥2 years of prior enrollment.

n = 43,501 patients

Results

risk of new eye inflammation was far lower than with a comparison multiple sclerosis drug

AHR by subgroup · 95% CI

More results

Sensitivity analysis confirmed findings for fumarates (aHR 0.56, 95% CI: 0.38-0.82) and nucleic acid synthesis inhibitors/S1P modulators (aHR 0.16, 95% CI: 0.08-0.33).

“

Conclusion · 1 of 2

Certain disease-modifying therapies classes are associated with a protective effect for noninfectious uveitis in multiple sclerosis.

Conclusion · 2 of 2

If confirmed, these medications could be targeted for personalized multiple sclerosis treatment and potentially repurposed to treat noninfectious uveitis in other patient populations.

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Related papers